<DOC>
	<DOCNO>NCT01848210</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety fixed-dose combination coumarin troxerutin versus placebo symptomatic treatment chronic venous insufficiency .</brief_summary>
	<brief_title>Efficacy Safety Coumarin Troxerutin Symptomatic Treatment Chronic Venous Insufficiency</brief_title>
	<detailed_description>The drug test study fixed-dose combination coumarin troxerutin call Venalot® . Venalot test treat symptom chronic venous insufficiency . This study look symptom relief people take Venalot® . The study enroll approximately 808 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Combination coumarin + troxerutin extend release tablet - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient . All participant ask take two tablet three time day throughout study . This multi-centre trial conduct Brazil . The overall time participate study 18 week . Participants make 6 visit clinic .</detailed_description>
	<mesh_term>Venous Insufficiency</mesh_term>
	<mesh_term>Troxerutin</mesh_term>
	<criteria>1 . Consent subject legal representative 2 . Men woman ethnicity , age 18 75 year , body mass index ( BMI ) equal less 40 . 3 . Is able use properly medication accord protocol . 4 . Has chronic venous insufficiency reference leg clinical classification C3 , C4a orC4b C5 , provide two last situation present lipodermatosclerosis compromise 1/3 portion leg immerse immersible plethysmometer . 5 . Has stable edema ( steady state ) , equivalent variation lower equal 10 % partial volume reference leg screen visit randomization visit , present least 6 month . 6 . Scoring `` Severity Score Local Complaints '' equal high 5 total point . 7 . Women use effective ( discretion investigator ) , hormonal , birth control method ( hormonal intrauterine device ( IUD ) , surgical sterilization , among others ) , postmenopausal , addition condom use ( mandatory ) . 1 . Has chronic venous insufficiency classify C1 , C2 reference leg C6 leg . 2 . Has chronic venous insufficiency C4b C5 reference leg , lipodermatosclerosis present 1/3 portion leg immerse plethysmometer . 3 . Has unstable edema , equivalent variation 10 % partial volume reference leg screen visit randomization visit , prior start treatment . 4 . Has venous obstruction and/or deep vein thrombosis ( DVT ) and/or presence phlebitis low limb last 3 ( three ) month . 5 . Has develop deep vein insufficiency last 3 ( three ) month . 6 . Has disease may interfere finding study : lymphedema , thrombosis , clot disorder , edema low limb due rightsided heart failure , arterial obstruction lower limbs condition , medical discretion , relevant exclusion , particularly symptom similar symptomatology chronic venous insufficiency . 7 . Has history surgery venous system sclerotherapy receive treatment chronic venous insufficiency last 03 month , whether drug , elastic stocking , laser , surgery . 8 . Has use previously Venalot® benefit treatment . 9 . Has previous history know suspect allergy intolerance ingredient medicinal product investigation . 10 . Has clinical finding ( history physical examination ) interpret physicianinvestigator risk participant 's participation study . 11 . Has know serious systemic disease , accord medical and/or laboratory history . 12 . Has history know liver disease hepatitis A , hepatitis B , C. 13 . Has change least one lab parameter : aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gammaglutamyltransferase ( gammaGT ) , alkaline phosphatase 2.5 time upper limit normal range ; hemoglobin less 10 g/dL ; clearance creatinine estimative equal 60mL/min/1.73 m^2 ; platelets 90,000/mL ; total bilirubin fraction 1.5 time normal value . 14 . Has use diuretic period less equal 6 month due disease ( hypertension , renal failure , ) . 15 . Has serious chronic liver kidney disease , accord medical and/or laboratory history . 16 . Has uncontrolled blood hypertension ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 100 mmHg ) randomization clinical hypertensive urgency . 17 . Has previous history diabetes mellitus use insulin . 18 . Has receive treatment immunosuppressive drug , include systemic corticosteroid within 30 day start study ( randomization visit ) , receive immunosuppressive treatment , know congenital acquire immunodeficiency . 19 . Has malignant neoplasm , etiology , receive type anticancer treatment , unless properly treat evidence recurrence last five year . Nonmelanoma skin cancer exclusion criterion . 20 . Is unable understand guideline specify protocol attend study visit . 21 . Has previous history alcoholism , drug abuse , psychological emotional problem last 5 year invalidate Informed Consent Form restrain participant 's ability comply requirement protocol . 22 . Pregnant breastfeed woman , potential become pregnant use appropriate contraceptive method . 23 . Women use hormonal contraceptive hormone replacement treatment , include phytoestrogens , within last 3 month . 24 . Took part clinical trial last year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>